title: Feasibility and efficacy of Thulium:YAG laser enucleation (VapoEnucleation) of the prostate.
abstract: OBJECTIVE
  Thulium:YAG (Tm:YAG) vaporesection has been introduced and efficiency was shown on smaller prostates. Criticism mainly referred to prolonged operation time in larger prostates, which appears to be a potential limitation compared to HoLEP. Aim of the study was to evaluate feasibility and efficiency of Tm:YAG VapoEnucleation in larger prostates.
  
  
  METHODS
  VapoEnucleation was performed using a 70 W continuous wave-laser. After enucleation tissue was morcellated within the bladder. Prospectively assessed outcomes were improvement in urodynamic parameter and the intra- and postoperative course. Complications were recorded.
  
  
  RESULTS
  A total of 88 consecutive patients with prostatic enlargement underwent VapoEnucleation. Prostatic volume was 61.3 +/- 24.0 cc (30-160). OR-time was 72 min +/- 26.6 (35-144) and laser-time 32.4 +/- 10.1 min (16.3-59.3). Applied laser energy was 123.7 +/- 40.6 kJ (67.8-240.9). An average of 31.7 +/- 18.3 g of tissue was retrieved. Pathology revealed four patients with incidental carcinoma. Foley catheter-time was 2 days and the suprapubic tube, if placed, was removed on the third postoperative day on average. Twelve complications were recorded, including bleeding (3), urinary tract infection (6), second-look procedure, due to insufficient deobstruction (2). Re-catherization after successful initial voiding trial was necessary in one patient. Mean peak flow rate improved from 3.5 +/- 4.7 to 19.8 +/- 11.6 ml/s and post-voiding residual urine decreased from 121.4 +/- 339.9 to 22.4 +/- 32.7 ml.
  
  
  CONCLUSIONS
  The functional outcomes demonstrate efficiency of Tm:YAG VapoEnucleation for patients with larger prostates. From our experience, learning curve in VapoEnucleation is short and complications are minimal. Theoretically, no limitation in prostate size occurs. Long-term follow-up is needed to prove durability.
authors.affiliation: Department of Urology, Asklepios Hospital Barmbek, Hamburg, Germany. thorsten.bach@uro.ma.uni-heidelberg.de
authors.forename: T
authors.initials: T
authors.lastname: Bach
authors.forename: G
authors.initials: G
authors.lastname: Wendt-Nordahl
authors.forename: M S
authors.initials: MS
authors.lastname: Michel
authors.forename: T R W
authors.initials: TR
authors.lastname: Herrmann
authors.forename: A J
authors.initials: AJ
authors.lastname: Gross
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D005240:Feasibility Studies; D006801:Humans; D053844:Lasers, Solid-State / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D019106:Postoperative Hemorrhage / Q000209:etiology; D011446:Prospective Studies; D011470:Prostatic Hyperplasia / Q000601:surgery*; D013932:Thulium / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D014552:Urinary Tract Infections / Q000209:etiology
chemical_list: D013932:Thulium